HK1257247A1 - 用於預防及治療杜興氏肌肉營養不良症的方法和組合物 - Google Patents

用於預防及治療杜興氏肌肉營養不良症的方法和組合物

Info

Publication number
HK1257247A1
HK1257247A1 HK18116306.5A HK18116306A HK1257247A1 HK 1257247 A1 HK1257247 A1 HK 1257247A1 HK 18116306 A HK18116306 A HK 18116306A HK 1257247 A1 HK1257247 A1 HK 1257247A1
Authority
HK
Hong Kong
Prior art keywords
prevention
compositions
treatment
methods
muscular dystrophy
Prior art date
Application number
HK18116306.5A
Other languages
English (en)
Inventor
D Travis Wilson
Original Assignee
D Travis Wilson
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by D Travis Wilson filed Critical D Travis Wilson
Publication of HK1257247A1 publication Critical patent/HK1257247A1/zh

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/08—Peptides having 5 to 11 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/07—Tetrapeptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/10—Tetrapeptides
    • C07K5/1002—Tetrapeptides with the first amino acid being neutral
    • C07K5/1016—Tetrapeptides with the first amino acid being neutral and aromatic or cycloaliphatic

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Physical Education & Sports Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Neurology (AREA)
  • Dermatology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
HK18116306.5A 2016-01-06 2018-12-19 用於預防及治療杜興氏肌肉營養不良症的方法和組合物 HK1257247A1 (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201662275369P 2016-01-06 2016-01-06
PCT/US2017/012532 WO2017120470A1 (en) 2016-01-06 2017-01-06 Methods and compositions for the prevention and treatment of duchenne muscular dystrophy

Publications (1)

Publication Number Publication Date
HK1257247A1 true HK1257247A1 (zh) 2019-10-18

Family

ID=59274284

Family Applications (1)

Application Number Title Priority Date Filing Date
HK18116306.5A HK1257247A1 (zh) 2016-01-06 2018-12-19 用於預防及治療杜興氏肌肉營養不良症的方法和組合物

Country Status (6)

Country Link
US (2) US20190022167A1 (zh)
EP (4) EP3895722A1 (zh)
CN (3) CN116196389A (zh)
CA (1) CA3010599A1 (zh)
HK (1) HK1257247A1 (zh)
WO (1) WO2017120470A1 (zh)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3606938A1 (en) 2017-04-05 2020-02-12 Stealth BioTherapeutics Corp Crystalline salt forms of boc-d-arg-dmt-lys-(boc)-phe-nh2
US11325943B2 (en) 2017-06-02 2022-05-10 Stealth Biotherapeutics Inc. Crystalline salt forms of SBT-20
US10676506B2 (en) 2018-01-26 2020-06-09 Stealth Biotherapeutics Corp. Crystalline bis- and tris-hydrochloride salt of elamipretide
CA3110297A1 (en) * 2018-08-23 2020-02-27 Zion Medical B.V Pharmaceutical compositions comprising integration-promoting peptides
EP3952867A4 (en) * 2019-04-10 2023-01-11 PTC Therapeutics, Inc. METHOD FOR THE TREATMENT OF DUCHENNE MUSCULAR DYSTROPHY MEDIATED BY A NONSENSE MUTATION IN PEDIATRIC PATIENTS
EP4077687A1 (en) * 2019-12-20 2022-10-26 Research Institute at Nationwide Children's Hospital Optimized gene therapy for targeting muscle in muscle diseases
WO2021257673A2 (en) * 2020-06-17 2021-12-23 Stealth Biotherapeutics Inc. Methods and compositions for the treatment of muscular dystrophy
WO2023107611A1 (en) * 2021-12-09 2023-06-15 Stealth Biotherapeutics Inc. Methods and compositions for the treatment or prevention of muscular dystrophy

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4522811A (en) 1982-07-08 1985-06-11 Syntex (U.S.A.) Inc. Serial injection of muramyldipeptides and liposomes enhances the anti-infective activity of muramyldipeptides
US5858784A (en) 1991-12-17 1999-01-12 The Regents Of The University Of California Expression of cloned genes in the lung by aerosol- and liposome-based delivery
US5674534A (en) 1992-06-11 1997-10-07 Alkermes, Inc. Composition for sustained release of non-aggregated erythropoietin
US5716644A (en) 1992-06-11 1998-02-10 Alkermes, Inc. Composition for sustained release of non-aggregated erythropoietin
US5989463A (en) 1997-09-24 1999-11-23 Alkermes Controlled Therapeutics, Inc. Methods for fabricating polymer-based controlled release devices
US6245740B1 (en) 1998-12-23 2001-06-12 Amgen Inc. Polyol:oil suspensions for the sustained release of proteins
WO2011106717A1 (en) * 2010-02-26 2011-09-01 University Of Florida Research Foundation, Inc. Mitochondrial-targeted antioxidants protect against mechanical ventilation-induced diaphragm dysfunction and skeletal muscle atrophy
IN2014MN00357A (zh) * 2011-08-30 2015-06-19 Medical Res Council
US9624282B2 (en) * 2012-11-26 2017-04-18 The Curators Of The University Of Missouri Microdystrophin peptides and methods for treating muscular dystrophy using the same
JP6475639B2 (ja) * 2013-01-25 2019-02-27 シャイアー ヒューマン ジェネティック セラピーズ インコーポレイテッド デュシェンヌ筋ジストロフィーの治療におけるフォリスタチン
EP3586867A3 (en) * 2013-01-28 2020-04-08 Shire Human Genetic Therapies, Inc. Placenta growth factor in treating duchenne muscular dystrophy
WO2015017861A1 (en) * 2013-08-02 2015-02-05 Stealth Peptides International, Inc. Methods and compositions for the prevention and treatment of friedreich's ataxia
EP3502132A1 (en) * 2014-05-28 2019-06-26 Stealth BioTherapeutics Corp Therapeutic compositions including therapeutic small molecules and uses thereof

Also Published As

Publication number Publication date
EP3399993A1 (en) 2018-11-14
CN116196388A (zh) 2023-06-02
EP3399993A4 (en) 2019-07-17
EP4233887A1 (en) 2023-08-30
CN116196389A (zh) 2023-06-02
US20230109564A1 (en) 2023-04-06
CN109152810A (zh) 2019-01-04
EP3399993B1 (en) 2021-03-31
EP4085920A1 (en) 2022-11-09
EP3895722A1 (en) 2021-10-20
WO2017120470A1 (en) 2017-07-13
CA3010599A1 (en) 2017-07-13
US20190022167A1 (en) 2019-01-24

Similar Documents

Publication Publication Date Title
IL290160A (en) Preparations and methods for the treatment of Duchenne muscular dystrophy and related disorders
HK1244838A1 (zh) 用於治療杜興氏肌肉營養不良症和貝克型肌肉營養不良症的與crispr/cas相關的方法及組合物
HK1258205A1 (zh) 用於治療血紅蛋白病的組合物和方法
EP3452498A4 (en) CRISPR / CAS RELATED METHODS AND COMPOSITIONS FOR TREATING DUCHENNE MUSCLE DYSTROPHY
HK1257247A1 (zh) 用於預防及治療杜興氏肌肉營養不良症的方法和組合物
HK1253769A1 (zh) 用於診斷和治療腎上腺腦白質營養不良的方法和組合物
EP3207048A4 (en) Compositions and methods of treating muscular dystrophy
ZA201707303B (en) Compositions and methods for the treatment of immunodeficiency
ZA201900960B (en) Methods and compositions for the treatment of cancer
EP3182989A4 (en) Methods and compositions for the prevention and treatment of disease
SG11201702554QA (en) Compositions and methods for the treatment of multiple sclerosis
IL263477A (en) Compositions and methods for the treatment or prevention of oxalate-related disorders
IL265791A (en) Compositions and methods for treating dry mouth
PT3286317T (pt) Inibidor de dinamina 2 para o tratamento de distrofia muscular de duchenne
HK1258502A1 (zh) 用於治療高胱氨酸尿症的組合物和方法
HK1257853A1 (zh) 用於治療和預防放射性皮炎的組合物和方法
ZA201808232B (en) Compositions and methods for the treatment of cancer
EP3341006A4 (en) COMPOSITIONS AND METHODS FOR TREATING NERVE DAMAGE
ZA201900984B (en) Methods and compositions for the treatment of warts
IL264467B (en) Compounds and methods for the treatment of irritable bowel syndrome
ZA201706985B (en) Compositions for the treatment of fibrosis and fibrosis-related conditions
DK3313207T3 (en) Compositions and methods for the treatment of malnutrition
EP3294339A4 (en) METHODS AND COMPOSITIONS FOR THE TREATMENT OF ARTHRITIS
IL262013A (en) Composition for the treatment of duchenne muscular dystrophy
GB201612920D0 (en) Composition for the treatment of Duchenne Muscular Dystrophy